İçeriğe geç
akaturk Akademik ölçüm

Akademisyen profili · PROFESÖR

MEHMET ARTAÇ

NECMETTİN ERBAKAN ÜNİVERSİTESİ

  • TIP FAKÜLTESİ
  • DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Makale YÖKSİS 173
Proje 1
Kitap 6
Bildiri 68
Patent 0
Sanatsal 0
Scopus (SJR)
Q1 37 Q2 37 Q3 54 Q4 11
WoS (JCR)
Q1 21 Q2 19 Q3 34 Q4 61
TR Index 19 makale

Scopus (SJR)

WoS (JCR)

TR Index

19 makale

Toplam 173 yayın

Makaleler

  1. 2025 Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy Journal of Oncology Pharmacy Practice DOI 10.1177/10781552241279537
  2. 2025 Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program BMC Cancer DOI 10.1186/s12885-025-15287-2
  3. 2025 The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study Journal of Chemotherapy DOI 10.1080/1120009X.2025.2601938
  4. 2025 Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study Scientific Reports DOI 10.1038/s41598-025-19899-3
  5. 2025 Small cell lung cancer differentiation in patients with driver mutant non-small cell lung cancer: a single center experience Journal of Cancer Research and Clinical Oncology DOI 10.1007/s00432-025-06194-x
  6. 2025 Lorlatinib experience in a patient with ALK + non-small cell lung cancer on hemodialysis: A case report Journal of Oncology Pharmacy Practice DOI 10.1177/10781552241271791
  7. 2025 Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib Medicina DOI 10.3390/medicina61101843
  8. 2025 Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study Frontiers in Immunology DOI 10.3389/fimmu.2025.1693295
  9. 2025 Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach Cancers DOI 10.3390/cancers17020233
  10. 2025 A preliminary study on the prognostic significance of cysteine-rich EGF ligand domain 2 protein (CRELD2) in patients with triple negative breast cancer Biomolecules and Biomedicine DOI 10.17305/bb.2024.11865
  11. 2025 Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy The Breast DOI 10.1016/j.breast.2025.104669
  12. 2025 Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer Journal of Oncology Pharmacy Practice DOI 10.1177/10781552241276191
  13. 2025 Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study The Lancet Respiratory Medicine DOI 10.1016/S2213-2600(25)00209-7
  14. 2025 Impact of Body Composition on Progression-Free Survival in Patients with Metastatic Breast Cancer Treated with Ribociclib Current Oncology DOI 10.3390/curroncol32090510
  15. 2025 Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer JAMA Oncology DOI 10.1001/jamaoncol.2025.2026
  16. 2025 Artificial intelligence and patient narratives: A novel approach to assessing hope in patients with cancer Medicine International DOI 10.3892/mi.2025.240
  17. 2024 Rare case of myelodysplastic syndrome with excess blasts 2 developing after adjuvant chemoradiotherapy for triple-negative breast cancer in a patient with Bloom syndrome Strahlentherapie und Onkologie DOI 10.1007/s00066-024-02257-z
  18. 2024 Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases Scientific Reports DOI 10.1038/s41598-024-56046-w
  19. 2024 Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study Current Medical Research and Opinion DOI 10.1080/03007995.2024.2366430
  20. 2024 Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study BMC Cancer DOI 10.1186/s12885-023-11203-8

Akademisyenlere dön